Status:
COMPLETED
Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders
Lead Sponsor:
Gruppo Italiano Studio Linfomi
Conditions:
Chronic Lymphocytic Leukaemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is collect and evaluate the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refract...
Detailed Description
All patients who meet the criteria for inclusion will be included in the study. A specific database will be created to collect the following information: personal data, medical history, histology rela...
Eligibility Criteria
Inclusion
- patients with relapsed or refractory chronic lymphoproliferative disorders
- salvage treatment with Bendamustine +/- Rituximab
- age ≥ 18 years
Exclusion
- previous treatment with Bendamustine
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT01832597
Start Date
November 1 2010
End Date
January 1 2011
Last Update
April 16 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
UO di Ematologia, S.O. Annunziata
Cosenza, CZ, Italy, 87100
2
Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Universita' di Modena e Reggio Emilia
Modena, MO, Italy, 41124
3
UO di Ematologia, AOUP Paolo Giaccone,
Palermo, PA, Italy, 90127